New immunotherapy combo shows promise for tough lung cancer

NCT ID NCT04063163

Completed Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested whether adding an experimental immunotherapy drug called HLX10 to standard chemotherapy could help people with extensive-stage small cell lung cancer live longer. The study enrolled 585 people who had not received prior treatment. Participants were randomly assigned to receive either HLX10 plus chemo or a placebo plus chemo. The main goal was to see if the combination improved overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HLX10 (a PD-1 inhibitor) combined with chemotherapy (carboplatin and etoposide)
What this could lead to: If successful, this combination could become a new first-line treatment option for extensive-stage small cell lung cancer, potentially improving survival.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. Adding immunotherapy to chemo may increase side effects, and not all patients may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Contacts and locations

Locations

Arkhangelsk Clinical Oncology Dispensary

Arkhangelsk, Russia
Institute for Personalized Medicine

Tbilisi, Georgia
Komunalnyi zaklad Miska bahato

Dnipropetrovsk, Ukraine
Medipol Mega Hospital

Istanbul, Turkey (Türkiye)
Wojew. Wielospecjalistyczne Centrum Onkologii i Traumatologi

Lodz, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.